Vabicaserin
- Generic Name
- Vabicaserin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C15H20N2
- CAS Number
- 887258-95-9
- Unique Ingredient Identifier
- WD9550HPNL
- Background
Vabicaserin has been used in trials studying the health services research and treatment of Schizophrenia.
- Associated Conditions
- -
- Associated Therapies
- -
Comparative Formulation Study of Vabicaserin
- First Posted Date
- 2009-06-26
- Last Posted Date
- 2009-09-11
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 15
- Registration Number
- NCT00928551
Study Evaluating Vabicaserin in Subjects With Schizophrenia
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-11-26
- Last Posted Date
- 2014-03-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 199
- Registration Number
- NCT00563706
- Locations
- 🇨🇦
Pfizer Investigational Site, Kingston, Ontario, Canada
Study Comparing Bioavailability of Oral Formulations of Vabicaserin
Phase 1
Completed
- Conditions
- First Posted Date
- 2007-10-10
- Last Posted Date
- 2007-12-05
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Registration Number
- NCT00541996
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath